Discovery of a vorapaxar analog with increased aqueous solubility

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6676-6679

  Xia, Yan ^a   Chackalamannil, Samuel ^a   Greenlee, William J ^a   Wang, Yuguang ^a,b   Hu, Zhiyong ^a   Root, Yuriko ^a   Wong, Jesse ^a   Kong, Jianshe ^a   Ahn, Ho Sam ^a   Boykow, George ^a   Hsieh, Yunsheng ^a   Kurowski, Stan ^a   Chintala, Madhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ChemExplorer Co Ltd   (China)

Author keywords

PAR 1 antagonist; SCH 530348 analog; SCH 602539; Solubility; Thrombin receptor antagonist; Vorapaxar analog

Indexed keywords

THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VORAPAXAR;

AQUEOUS SOLUTION; ARTICLE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; MONKEY; THROMBOCYTE AGGREGATION;

ANIMALS; DRUG DISCOVERY; HUMANS; INHIBITORY CONCENTRATION 50; LACTONES; MACACA FASCICULARIS; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, THROMBIN; SOLUBILITY; WATER;

MACACA FASCICULARIS;

EID: 77958040965     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.009     Document Type: Article

References (26)

1. J.F. Viles-Gonzalez, V. Fuster, and J.J. Badimon Eur. Heart J. 25 2004 1197
2. American Heart Association. Heart Disease and Stroke Statistics - 2009 Update. Dallas, Texas, 2009.
3. Y. Yeghiazarians, J.B. Braunstein, A. Askari, and P.H. Stone N. Eng. J. Med. 342 2000 101
4. P. Libby Circulation 104 2001 365
5. S. Chackalamannil, Y. Wang, W.J. Greenlee, Z. Hu, Y. Xia, H.-S. Ahn, G. Boykow, Y. Hsieh, J. Palamanda, J. Agans-Fantuzzi, S. Kurowski, M. Graziano, and M. Chintala J. Med. Chem. 51 2008 3061 and references cited therein
6. The TRA CER Executive and Steering Committees. Am. Heart J. 2009, 158, 327.
7. D.A. Morrow, B.M. Scirica, K.A. Fox, G. Berman, J. Strony, E. Veltri, M.P. Bonaca, P. Fish, C.H. McCabe, and E. Braunwald Am. Heart J. 158 2009 335
8. M.P. Bonaca, and D.A. Morrow Future Cardiol. 5 2009 435
9. 6
10. S. Goto, T. Yamaguchi, Y. Ikeda, K. Kato, H. Yamaguchi, and P. Jensen J. Atheroscler. Thromb. 17 2010 156
11. S.R. Coughlin J. Thromb. Haemost. 3 2005 1800
12. T.-K.H. Vu, D.T. Hung, V.I. Wheaton, and S.R. Coughlin Cell 64 1991 1057
13. For recent reviews on thrombin receptor (PAR-1) antagonists as antithrombotic agents, see: S. Chackalamannil J. Med. Chem. 49 2006 5389
14. S. Chackalamannil, and Y. Xia Expert Opin. Ther. Pat. 16 2006 493
15. R.M. Scarborough, A. Pandey, and X. Zhang Annu. Rep. Med. Chem. 40 2005 85
16. B.E. Maryanoff, H.-C. Zhang, P. Andrade-Gordon, and C.K. Derian Curr. Med. Chem.: Cardiovasc. Hematol. Agents 1 2003 13
17. Y. Xia, S. Chackalamannil, M. Clasby, D. Doller, K. Eagen, W.J. Greenlee, H. Tsai, J. Agans-Fantuzzi, Ho-Sam Ahn, G.C. Boykow, Y. Hsieh, C.A. Lunn, and M. Chintala Bioorg. Med. Chem. Lett. 17 2007 4509
18. M.C. Clasby, S. Chackalamannil, M. Czarniecki, D. Doller, K. Eagen, W.J. Greenlee, G. Kao, Y. Lin, H. Tsai, Y. Xia, H.-S. Ahn, J. Agans-Fantuzzi, G. Boykow, M. Chintala, C. Foster, A. Smith-Thoran, K. Alton, M. Bryant, Y. Hsieh, J. Lau, and J. Palamanda J. Med. Chem. 50 2007 129
19. M.V. Chelliah, S. Chackalamannil, Y. Xia, K. Eagen, M.C. Clasby, X. Gao, W. Greenlee, H.-S. Ahn, J. Agans-Fantuzzi, G. Boykow, Y. Hsieh, M. Bryant, J. Palamanda, T.-M. Chan, D. Hesk, and M. Chintala J. Med. Chem. 50 2007 5147
20. 50 <100 nM) were assayed multiple times (n ≥5, SD ± 20%).
21. S. Chackalamannil, Y. Xia, W.J. Greenlee, M. Clasby, D. Doller, H. Tsai, T. Asberom, M. Czarniecki, H.-S. Ahn, G. Boykow, C. Foster, J. Agans-Fantuzzi, M. Bryant, J. Lau, and M. Chintala J. Med. Chem. 48 2005 5884
22. Kinetic solubility test: The nephelometry (light scattering) method was used. The test compound (1.0 mg) was dissolved in DMSO to produce a 25 mM stock. A serial dilution into DMSO was performed on a robotic system and 3 μL of the compound in DMSO at various concentrations was added to the buffer (10 mM phosphate, pH 7.4). Following equilibration at room temperature for 30 min, the presence of precipitate was detected by nephelometry. Solubility was defined as the highest concentration of test compound that did not scatter light. Also, see: C.A. Lipinski J. Pharmacol. Toxicol. Methods 44 2001 235
23. K.A. Cox, K. Dunn-Meynell, W.A. Kormacher, L. Broske, A.A. Nomeir, C.C. Lin, M.N. Cayen, and W.H. Barr Drug Discovery Today 4 1999 232
24. For details of the ex vivo platelet aggregation assay in cynomolgus monkeys, see Ref. 12.
25. X. Cui, A. Thomas, V. Gerlach, R.E. White, R.A. Morrison, and K.-C. Cheng Biochem. Pharmacol. 76 2008 680
26. M. Chintala, S. Kurowski, S. Vemulapalli, Q. Li, A. Brown, and J. Strony Eur. Heart J. 28 2007 188